COMP <GO>
ILMN vs CI // REVENUE GROWTH (YOY)
Illumina Inc. (NASDAQ) VS. The Cigna Group (NYSE) • 15-METRIC TALLY: ILMN 9
— CI 5
▲ REVENUE GROWTH (YOY) LEADER: CI
LAST: $235.99 (-18.64%) • MKT CAP: $43.80B
revenue-growth
-0.70%
LAST: $298.23 (-0.06%) • MKT CAP: $78.85B
revenue-growth
11.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ILMN VS. CI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ILMN | CI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 66.10% | 21.80% | +44.30 | ILMN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.20% | 8.80% | +9.40 | ILMN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 47.5x | 6.1x | +41.40 | CI | /valuation <GO> |
| Free Cash Flow Yield | 2.13% | -3.51% | +5.64 | ILMN | /fcf-yield <GO> |
| Operating Margin | 18.60% | 3.30% | +15.30 | ILMN | /operating-margins <GO> |
| Net Profit Margin | 19.60% | 2.20% | +17.40 | ILMN | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -0.70% | 11.20% | -11.90 | CI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.04% | -2.04 | CI | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.52 | 2.70 | +6.82 | ILMN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | ILMN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.1 | 55.8 | +1.30 | ILMN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.16 | 1.12 | +0.04 | ILMN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 47.9x | 12.3x | +35.60 | CI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $43.80B | $78.85B | -$35.05B | CI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ILMN REV | CI REV | ILMN GROSS % | CI GROSS % | ILMN FCF | CI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.34B | $274.90B | 66.1% | 21.8% | $931.0M | -$2.77B |
| FY 2024 | $4.37B | $247.12B | 65.4% | 26.1% | $709.0M | -$757.4M |
| FY 2023 | $4.50B | $195.26B | — | — | $275.3M | $3.03B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ILMN // BETA 1.16
CI // BETA 1.12